Ix Biopharma
Ix Biopharma Ltd, headquartered in Singapore (SG), is a pioneering biopharmaceutical company specialising in the development of innovative drug delivery systems. Founded in 2008, Ix Biopharma has made significant strides in the industry, particularly with its proprietary WaferiX™ technology, which enhances the delivery of therapeutics through sublingual administration. The company focuses on pain management and other therapeutic areas, offering unique products that provide rapid onset and improved bioavailability. With a strong commitment to research and development, Ix Biopharma has positioned itself as a leader in the biopharmaceutical sector, achieving notable milestones in product development and regulatory approvals. Its dedication to advancing patient care through innovative solutions underscores its reputation as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 12 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ix Biopharma's reported carbon emissions
In 2023, Ix Biopharma reported carbon emissions of approximately 937,000 kg CO2e, all of which fall under Scope 2 emissions. This figure represents a slight increase from the previous year’s emissions of about 714,000 kg CO2e in 2022, but a decrease from 2021's total of approximately 997,000 kg CO2e. For 2024, the company anticipates emissions to rise slightly to about 949,000 kg CO2e. Despite these fluctuations, Ix Biopharma has not established specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies indicates a need for further development in their sustainability efforts. As the company is headquartered in Singapore (SG), it operates within a global context that increasingly prioritises carbon neutrality and sustainable practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ix Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
